Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Cytos Rises After Confirming Drug Trial Timeline: Zurich Mover

Jan. 16 (Bloomberg) -- Cytos Biotechnology AG, a Swiss developer of an experimental drug for allergic asthma, rose to the highest in almost three months after saying a problem with a trial of the product won’t delay results of the study.

Cytos climbed 3 percent to 4.41 Swiss francs in Zurich, the highest price since Oct. 24, giving the company a market value of 98.8 million Swiss francs ($106 million). Almost 270,000 shares changed hands, more than three times the average three-month daily volume. The stock has advanced 56 percent this year, for the second-best gain on the Swiss Performance Index.

Cytos will replace material to be used in the trial of its CYT003 drug after a “technical issue” was discovered with the rubber stoppers used to close injection vials, the Schlieren, Switzerland-based company said in a statement today.

“Overall guidance for the clinical trial remains unchanged,” Cytos said. The first results from the study will be available in the first half of next year, it said.

To contact the reporter on this story: Simeon Bennett in Geneva at

To contact the editor responsible for this story: Phil Serafino at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.